GlassScriptPhysician profile
Charles P Bean
NPI 1053498519
$8,455.95
in general payments reported to CMS, 2019-2025
43 companies · $3,690 in 2025
The $3,690 reported for 2025 was more than what 98% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $829 · 2022: $619 · 2023: $1,664 · 2024: $1,654 · 2025: $3,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,025 · Travel and Lodging: $805 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,025.29 |
| Travel and Lodging | $804.55 |
| Education | $177.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,371.33 | 2021-2025 | Rezum Generator, Axonics, Ams 800 Artificial Urinary Sphincter |
| Sumitomo Pharma America, INC. | $798.23 | 2023-2025 | Orgovyx, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $731.38 | 2021-2025 | |
| Accord Healthcare, INC. | $580.33 | 2022-2025 | |
| Astellas Pharma US INC | $544.32 | 2021-2025 | Veozah, Myrbetriq, Xtandi |
| Myriad Genetic Laboratories, INC. | $491.52 | 2023-2025 | Prolaris |
| Pfizer INC. | $454.47 | 2023-2025 | |
| Endo Pharmaceuticals INC. | $414.39 | 2021-2024 | Xiaflex, Aveed |
| Abbvie INC. | $401.28 | 2021-2025 | |
| Dendreon Pharmaceuticals LLC | $313.91 | 2024-2025 | Provenge |
| Axonics, INC. | $308.59 | 2022-2024 | Axonics |
| Ferring Pharmaceuticals INC. | $226.77 | 2024-2025 | Adstiladrin |
| Janssen Biotech, INC. | $202.61 | 2023-2025 | Erleada, Akeega |
| Procept Biorobotics Corporation | $161.72 | 2025 | |
| Teleflex LLC | $140.88 | 2024 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $130.76 | 2024-2025 | Xiaflex, Aveed |
| Merck Sharp & Dohme LLC | $109.23 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $93.00 | 2025 | |
| Verity Pharmaceuticals INC. | $89.14 | 2024-2025 | Trelstar |
| Rochester Medical Corporation | $64.60 | 2021 | |
| Antares Pharma, INC. | $60.30 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Laborie Medical Technologies Corp. | $57.53 | 2025 | Esense 7fr Abdominal Catheter, Optilume Bph Drug Coated Balloon Catheter |
| Novartis Pharmaceuticals Corporation | $56.13 | 2022-2025 | |
| Travere Therapeutics, INC. | $55.58 | 2021-2022 | |
| Tolmar, INC. | $53.74 | 2024-2025 | Jatenzo, Eligard |
| Astrazeneca Pharmaceuticals LP | $50.35 | 2022-2023 | Lynparza |
| Myovant Sciences INC. | $50.15 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $48.82 | 2023-2025 | Pylarify |
| Coloplast Corp | $48.22 | 2021-2023 | Altis |
| Halozyme INC | $45.33 | 2023 | |
| Urogen Pharma, INC. | $45.15 | 2025 | |
| 180 Medical, INC. | $39.79 | 2021-2025 | |
| Blue Earth Diagnostics | $33.86 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $26.69 | 2022-2023 | Seglentis |
| Innovation Technologies INC | $25.44 | 2025 | Irrisept |
| Clarus Therapeutics INC. | $23.62 | 2021 | |
| Immunitybio, INC. | $21.95 | 2025 | |
| Ethicon US, LLC | $18.37 | 2024 | Echelon Endopath, Echelon Flex, Harmonic |
| Smith+Nephew, INC. | $15.10 | 2022 | |
| Acerus Pharmaceuticals Corporation | $14.19 | 2021 | |
| Cardinal Health 414 LLC | $13.75 | 2023 | |
| Abbott Laboratories | $13.39 | 2024 | Proclaim |
| Ambu INC. | $10.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Bean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.